Patient dosing is expected to be completed in the December...

Patient dosing is expected to be completed in the December quarter of 2021 with results due in first quarter
of 2022. These results will be used to support an investigational new drug (IND) application with the FDA and
to inform the design of subsequent clinical trials. In July 2021, confidential interim analysis of the data from
the clinical trial was performed and these results were used to support a patent application regarding the
methods for the treatment of OSA.
Incannex has also commenced an open label extension to the phase 2 clinical trial. The open label extension
study has recruited people who have experienced a benefit from IHL-42X in the phase 2 trial and will assess
the therapeutic benefit and tolerability of IHL-42X in those patients over an extended timeframe of 6 months.
Just confirms positive results once again and why engage further capsule production if results were tepid!
risk reducing every day.